Chronic News and Research

RSS

Study on spinal cord stem cells paves way for post stroke symptom treatment

Neuralstem, Inc. announced that its spinal cord stem cells survived in rat brains affected by stroke and differentiated predominantly into neurons. The transplanted animals showed significant improvement in some motor skill and strength measurements. The study entitled, "Intracerebral Implantation of Adherent Human Neural Stem Cells To Reverse Motor Deficits in Chronic Stroke Rats," was presented earlier today by senior study author, Dr. Shinn-Zong Lin, M.D., Ph.D., at the Stem Cells USA & Regenerative Medicine Conference

15 Sep 2010

Heart patients with Type D personality at higher risk of future cardiovascular problems

Heart patients with the "distressed" (Type D) personality profile may face a higher risk of future cardiovascular problems, according to a summary article published in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.

15 Sep 2010

FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy

Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARC-4558 for the treatment of pain associated with Painful Diabetic Neuropathy (PDN).

15 Sep 2010

Aspirin can prevent stroke and heart attacks: Study

In a large scale Australian study, researchers have found that Aspirin can save lives and drastically reduce rates of stroke and heart attack.

15 Sep 2010

$Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy$

Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy

Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

15 Sep 2010

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced results from a pre-clinical pharmacokinetic study showing the ability of NexACT to enable rectal delivery of biologics, such as human antibodies.

15 Sep 2010

CSC launches new educational program to enhance lymphoma patient, physician communication

The Cancer Support Community (CSC), uniting The Wellness Community and Gilda's Club Worldwide, announced today the launch of Framing Life With Lymphoma, a new educational program designed to enhance lymphoma patient and physician communication.

14 Sep 2010

Enrollment in Derma Sciences DSC127 Phase 2 trial in diabetic foot ulcer healing to conclude September end

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that patient screening in its DSC127 Phase 2 trial in diabetic foot ulcer healing will be completed tomorrow, and that enrollment in the trial will conclude on September 30. This randomized, double-blind, placebo controlled study of up to 75 patients will look at the percentage of diabetic ulcers completely healed over a 12-week period, among other outcomes.

14 Sep 2010

AstraZeneca Chief Scientist shares enthusiasm for collaborative clinical research

The pharmaceutical industry must ensure an improved record of delivery by providing high quality, cost effective solutions to well defined unmet needs. This can be achieved through strategic collaborations that strengthen disease knowledge and provide improved tools to strengthen therapeutic target validation and to monitor therapeutic efficacy, says Andy Dray, Chief Scientist at AstraZeneca.

14 Sep 2010

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of preclinical data in the Journal of Neuroimmunology finding that its lead development candidate VB-201 significantly delayed the onset and severity of experimental autoimmune encephalomyelitis (EAE) in mice, the commonly used Multiple sclerosis.

14 Sep 2010

Guidance allowing children with life-limiting illness to receive both hospice care and curative treatments praised

The families of dying children who are covered under Medicaid or the Medicaid expansion Children's Health Insurance Program (CHIP) will no longer face the choice of stopping curative treatments in order for their terminally ill child to receive quality end-of-life care from hospice.

14 Sep 2010

RS Medical receives Federal Supply Schedule contract

International Rehabilitative Sciences, Inc. d/b/a RS Medical, announced today its first award of a Federal Supply Schedule contract. The contract is in effect through June 14, 2015.

14 Sep 2010

Cell-enriched primary renal cells improve survival and augment kidney function in CKD rodents

Tengion, Inc., a leader in regenerative medicine, announced today the publication of a key study in the American Journal of Physiology Renal Physiology by researchers at Tengion. In the study, rodents with chronic kidney disease (CKD) were treated with healthy kidney cells to catalyze the regeneration of functional kidney tissue and delay disease progression, as evidenced by extended survival, improved kidney filtration, and reduced severity of kidney tissue pathology.

14 Sep 2010

BC-CfE study finds links between insite use, addiction treatment and stopping injection drug use

A study led by researchers at the BC Centre for Excellence in HIV/AIDS (BC-CfE) at St. Paul's Hospital and the University of British Columbia has found that supervised injection facilities such as Vancouver's Insite connect clients with addiction treatment, which in turn resulted in greater likelihood of stopping injection drug use for at least six months.

14 Sep 2010

Sorghum bran contains high antioxidant, anti-inflammatory properties: Study

A new University of Georgia study has found that select varieties of sorghum bran have greater antioxidant and anti-inflammatory properties than well-known foods such as blueberries and pomegranates.

14 Sep 2010

OSUCCC-James researchers identify experimental agent that targets chronic lymphocytic leukemia

Researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) have identified an experimental agent that targets chronic lymphocytic leukemia and perhaps other proliferative disorders of lymphocytes.

14 Sep 2010

AskBio enters patent license agreement with Pfizer for HCV therapy

Asklepios BioPharmaceutical, Inc., a privately-owned clinical-stage biotechnology company, announced today it has entered into a patent license agreement with Pfizer, Inc. granting Pfizer access to certain proprietary gene-delivery platform technologies developed by AskBio, for use in developing novel therapies for patients with Hepatitis C virus (HCV).

14 Sep 2010

St. John Hospital commences enrollment in CONNECT trial for peripheral artery disease

St. John Hospital and Medical Center in Detroit and Avinger, Inc., a medical device company focused on the development of innovative devices to combat peripheral artery disease, announced today the enrollment of the first patient in the CONNECT (Chronic TOtal OcclusioN CrossiNg with thE WildCat CatheTer) clinical trial.

14 Sep 2010

Arno Therapeutics closes private placement to advance cancer treatment

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced that it has closed a private placement of its securities resulting in gross proceeds to the company of over $15 million.

14 Sep 2010

Study finds new therapeutic target for polycystic kidney disease

In work suggesting a new approach to treating polycystic kidney disease (PKD), a leading cause of kidney failure, researchers at Children's Hospital Boston were able to block the formation of fluid-filled cysts, the hallmark of the disease, in a mouse model. Their findings, using a compound that inhibits a receptor known as c-Met, will be published in the September 13th online edition of the Journal of Clinical Investigation.

14 Sep 2010

Chronic News and Research

Study on spinal cord stem cells paves way for post stroke symptom treatment

Heart patients with Type D personality at higher risk of future cardiovascular problems

FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy

Aspirin can prevent stroke and heart attacks: Study

Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

CSC launches new educational program to enhance lymphoma patient, physician communication

Enrollment in Derma Sciences DSC127 Phase 2 trial in diabetic foot ulcer healing to conclude September end

AstraZeneca Chief Scientist shares enthusiasm for collaborative clinical research

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

Guidance allowing children with life-limiting illness to receive both hospice care and curative treatments praised

RS Medical receives Federal Supply Schedule contract

Cell-enriched primary renal cells improve survival and augment kidney function in CKD rodents

BC-CfE study finds links between insite use, addiction treatment and stopping injection drug use

Sorghum bran contains high antioxidant, anti-inflammatory properties: Study

OSUCCC-James researchers identify experimental agent that targets chronic lymphocytic leukemia

AskBio enters patent license agreement with Pfizer for HCV therapy

St. John Hospital commences enrollment in CONNECT trial for peripheral artery disease

Arno Therapeutics closes private placement to advance cancer treatment

Study finds new therapeutic target for polycystic kidney disease

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News